Firebrick Pharma Ltd News

Firebrick Pharma Raises AU$800,000 via Placement

Firebrick Pharma (ASX:FRE) received binding commitments for a placement of AU$800,000 from a substantial shareholder, comprising 16 million shares at a discounted price of AU$0.05 apiece, according to

MT NewswiresMay 16 23:44 ET

Firebrick Pharma Sees Substantial Holder up Stake to 12% in Placement

Betadine-like nasal spray provider Firebrick Pharma (ASX:FRE) – whose flagship product Nasodine has recently gone live for sale in the US – has raised $0.8M in a placement largely backed by an existing substantial holder.

The Market HeraldMay 16 20:27 ET

Firebrick Pharma Appoints Auditor

Firebrick Pharma (ASX:FRE) appointed BDO Audit as company auditor, according to a Monday filing with the Australian bourse. The appointment follows the resignation of BDO Audit (WA) in line with the f

MT NewswiresMay 5 23:53 ET

Firebrick Pharma Launches Antiseptic Nasal Spray Into US Online Market

An antiseptic nasal spray developed by Melbourne-based Firebrick Pharma (ASX: FRE) to attack the common cold has been officially launched online for US customers.

Small CapsApr 16 21:56 ET

Stocks of the Hour: Firebrick Pharma, Critical Resources, Blue Star Helium

Firebrick Pharma (ASX:FRE) has announce that its Nasodine Nasal Spray product is being launched in the United States today. The product will be promoted for "nasal hygiene" without any therapeutic cla

sharecafeApr 16 21:50 ET

Firebrick Pharma's Nasodine Nasal Spray Enters US Market

Firebrick Pharma (ASX:FRE) is launching its Nasodine nasal spray in the US Wednesday, according to a same-day Australian bourse filing. The nasal spray can now be purchased from the company's US websi

MT NewswiresApr 16 19:57 ET

Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal

Firebrick Pharma's (ASX:FRE) phase 2 Covid-19 trial has been published in the Larynggoscope journal, according to a Tuesday Australian bourse filing. Price (AUD): $0.06, Change: $0.00, Percent Change:

MT NewswiresApr 3 17:04 ET

Firebrick Pharma to Release Shares From Escrow; Shares Rise 4%

Firebrick Pharma (ASX:FRE) is set to release 62,732,537 shares from escrow upon their expiry date on Jan. 28, according to a Friday filing. Two directors of the pharmaceutical firm own 30,054,412 shar

MT NewswiresJan 11 20:10 ET

Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray

Firebrick Pharma (ASX:FRE) withdrew its appeal with the Administrative Appeals Tribunal against the Therapeutic Goods Administration's decision not to approve Nasodine nasal spray. The pharmaceutical

MT NewswiresDec 27, 2023 02:28 ET

Firebrick Pharma Receives AU$1.8 Million R&D Tax Rebate

Firebrick Pharma (ASX:FRE) received a research and development tax incentive of AU$1.8 million for 2022/23. The tax rebate is mainly associated with costs incurred for clinical trials for Nasodine, wh

MT NewswiresOct 31, 2023 05:04 ET

Firebrick Says Independent Probe Into Nasodine Trial Results Did Not Find Errors

Firebrick Pharma (ASX:FRE) said an independent preliminary investigation into the Phase III trial results of the firm's Nasodine Nasal Spray "has not revealed any systematic error or other data issue"

MT NewswiresOct 4, 2023 08:15 ET

Firebrick Pharma's Cold Medication Fails Phase III Trial

Firebrick Pharma (ASX:FRE) said trial statisticians have completed their efficacy analysis of the "headline results" in the Phase III trial of firm's Nasodine Nasal Spray, being developed to treat com

MT NewswiresSep 13, 2023 08:16 ET

Firebrick Pharma Completes Enrollment for Cold Treatment Trial; Shares Soar 17%

Firebrick Pharma (ASX:FRE) completed the enrollment phase for its phase three trial investigating the use of the nasal spray Nasodine as a treatment for the common cold. The study was conducted on 500

MT NewswiresAug 9, 2023 01:43 ET